Vestjysk Bank A/S
13 January 2021
With reference to the company announcement previously issued by Vestjysk Bank A/S ("Vestjysk Bank") regarding the course of Vestjysk Bank's extraordinary general meeting of 13 January 2021, it is hereby announced that Vestjysk Bank has received notification of the result of the extraordinary general meeting of Den Jyske Sparekasse A/S ("Den Jyske Sparekasse").
The general meeting of Den Jyske Sparekasse has also adopted the proposal to execute the merger between Vestjysk Bank and Den Jyske Sparekasse.
The only outstanding condition for the merger between Vestjysk Bank and Den Jyske Sparekasse is the receipt of the Danish Financial Supervisory Authority's final approval for the proposed merger in accordance with section 204 of the Danish Financial Business Act, which is expected tomorrow, Thursday 14 January 2021, where the registration at the Danish Business Authority is also expected to be completed.
13 January 2021
Vestjysk Bank A/S
The Board of directors
Vestjysk Bank A/S
Torvet 4-5
DK-7620 Lemvig
Telephone +45 96 63 20 00
CVR-nr. 34 63 13 28
www.vestjyskbank.dk
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Robex Resources Inc.18.9.2025 08:01:56 CEST | Press release
Robex Announces Acceleration of Warrant Expiry Date
ONWARD Medical NV18.9.2025 07:30:00 CEST | Press release
Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy
Sampo plc18.9.2025 07:30:00 CEST | Press release
Sampo plc’s share buybacks 17 September 2025
Biotalys NV18.9.2025 07:00:00 CEST | Press release
Biotalys Reports Half-Year 2025 Financial Results and Business Highlights
F. Hoffmann-La Roche Ltd18.9.2025 07:00:00 CEST | Press release
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom